Hope you aren't getting any nasty sides.
So far so good. Will post back if anything changes.
Follow along with the video below to see how to install our site as a web app on your home screen.
Note: This feature may not be available in some browsers.
Hope you aren't getting any nasty sides.
@Demondosage
RAT CARCINOGENICITY STUDY WITH GW501516, A
PPAR DELTA AGONIST.
L. E. G
eiger
1
, W. S. Dunsford
2
, D. J. Lewis
2
, C. Brennan
3
, K. C. Liu
3
and S. J.
Newsholme
1
.
1
Safety Assessment, GlaxoSmithKline, King of Prussia, PA,
2
Safety
Assessment, GlaxoSmithKline, Ware, United Kingdom and
3
Huntingdon Life Sciences,
Huntingdon, United Kingdom.
GW501516, a non-genotoxic PPARδ agonist, was assessed for carcinogenic poten-
tial by daily administration (oral gavage) to Han Wistar rats for a period of 104
weeks. Males were given 0, 5, 15 or 30 mg/kg/day for the first 6 weeks of the study.
For the remainder of the study males were given 0, 5, 20 or 40 mg/kg/day. Females
were given 0, 3, 10 or 20 mg/kg/day for the entire study. GW501516 produced test
article-related neoplastic findings in multiple tissues at all doses. Increased mortal-
ity was seen with females given GW501516 at all doses and uterine endometrial
adenocarcinoma contributed to death in a high proportion of these animals.
Neoplasms considered test-article related occurred in the liver (hepatocellular ade-
noma at ≥10 mg/kg/day), urinary bladder (transitional cell carcinoma in males
given 20 and 40 mg/kg/day), thyroid (follicular cell adenoma at
≥3 mg/kg/day and carcinoma in males at ≥20 mg/kg/day), tongue (squamous cell papilloma in males at 5 mg/kg/day and 40 mg/kg/day), stomach (squamous cell papilloma in males at ≥5 mg/kg/day and a female at 20 mg/kg/day, and carcinoma in a male at 40 mg/kg/day and a female at 3 mg/kg/day), skin (inverted squamous cell papilloma in males at ≥5 mg/kg/day and females at 3 or 20 mg/kg/day), Harderian glands (ade-noma in males at ≥5 mg/kg/day and adenocarcinoma in a male at 40 mg/kg/day),
testes (interstitial cell adenoma at 40 mg/kg/day), ovary (Sertoli cell adenoma at
≥10 mg/kg/day) and uterus (polyp and endometrial adenocarcinoma at≥3
mg/kg/day). Some of the tumor types observed in this study have not been reported
with either PPARα or PPARγ agonists and may reflect tumor promotion mediated though
PPARδ agonism.
I have worked with Sarms in clinical studies in Germany. I'm telling you Sarms is the future. We would never test a Sarm in powder form, the properties are conducive to liquid suspension. Think of it this way, does Test have anabolic properties in powder form? Yes it does, is it much better and more anabolic in Suspension Hell yes. Its the same with Sarms.
Are the Sarms that are available right now as powerful as AAS, nope. But Sarms are the runner up when it comes to Anabolic return.
As I said the problem with Sarms is finding a good source, there are a few out there, just like their is a huge amount of good sources out their with AAS, but they also have a bunch of bunk crap.
Lets look at this way with powder formed Sarms, pretty straight forward on this one. Look at the companies that are pushing powdered Sarms, every single one of them pushed Pro Hormones. New law takes effect, your money maker gone, have tons of product left over. Buy some cheap Sarms and mix it with left over stock. Bam profit, get caught a little fine from the FDA. Also these companies where supplement companies now all of a sudden their research companies. There putting the middle finger up at the FDA, they market it like a supplement hell most of them are so ballsy that they don't even put For reseach purposes only on the bottle.
Best analogy I've seen in a whileComing here and talking about SARMS is like going to Ruth Chris steakhouse and asking for chicken fingers
